Nature Communications (Dec 2017)
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
- Ruogu Qi,
- Yongheng Wang,
- Peter M. Bruno,
- Haihua Xiao,
- Yingjie Yu,
- Ting Li,
- Sam Lauffer,
- Wei Wei,
- Qixian Chen,
- Xiang Kang,
- Haiqin Song,
- Xi Yang,
- Xing Huang,
- Alexandre Detappe,
- Ursula Matulonis,
- David Pepin,
- Michael T. Hemann,
- Michael J. Birrer,
- P. Peter Ghoroghchian
Affiliations
- Ruogu Qi
- Koch Institute for Integrative Cancer Research at MIT
- Yongheng Wang
- Koch Institute for Integrative Cancer Research at MIT
- Peter M. Bruno
- Koch Institute for Integrative Cancer Research at MIT
- Haihua Xiao
- Koch Institute for Integrative Cancer Research at MIT
- Yingjie Yu
- Koch Institute for Integrative Cancer Research at MIT
- Ting Li
- Koch Institute for Integrative Cancer Research at MIT
- Sam Lauffer
- Massachusetts General Hospital
- Wei Wei
- Massachusetts General Hospital
- Qixian Chen
- Koch Institute for Integrative Cancer Research at MIT
- Xiang Kang
- Koch Institute for Integrative Cancer Research at MIT
- Haiqin Song
- Koch Institute for Integrative Cancer Research at MIT
- Xi Yang
- Koch Institute for Integrative Cancer Research at MIT
- Xing Huang
- Koch Institute for Integrative Cancer Research at MIT
- Alexandre Detappe
- Koch Institute for Integrative Cancer Research at MIT
- Ursula Matulonis
- Dana Farber Cancer Institute
- David Pepin
- Massachusetts General Hospital
- Michael T. Hemann
- Koch Institute for Integrative Cancer Research at MIT
- Michael J. Birrer
- Massachusetts General Hospital
- P. Peter Ghoroghchian
- Koch Institute for Integrative Cancer Research at MIT
- DOI
- https://doi.org/10.1038/s41467-017-02390-7
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 12
Abstract
Improving the safety and efficacy of chemotherapeutics will help to enhance their effects. Here, the authors show that intraperitoneal delivery of nanoparticle conjugates of a potent toxin prolongs tumor inhibition and survival as compared to cisplatin in advanced-stage and platinum-resistant ovarian cancer mouse models.
